Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
$0.22
$0.22
$0.11
▼
$0.89
$11.42M0.5127,352 shsN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
$0.98
$0.98
$0.42
▼
$1.25
$11.17M0.9811,250 shsN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.20
$0.38
$0.18
▼
$2.14
$2.94M1.761.47 million shs386,117 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.03
$0.03
$0.01
▼
$0.04
$11.28M-1.184,445 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%+0.60%-36.99%-75.31%-89.90%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
$0.22
$0.22
$0.11
▼
$0.89
$11.42M0.5127,352 shsN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
$0.98
$0.98
$0.42
▼
$1.25
$11.17M0.9811,250 shsN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$0.20
$0.38
$0.18
▼
$2.14
$2.94M1.761.47 million shs386,117 shs
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$0.03
$0.03
$0.01
▼
$0.04
$11.28M-1.184,445 shsN/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00%0.00%0.00%0.00%0.00%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%+0.60%-36.99%-75.31%-89.90%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
0.00
N/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
0.00
N/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00
N/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/AN/AN/AN/A$0.58 per shareN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
$54.98M0.20$0.09 per share11.09($0.80) per share-1.22
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.10M2.67N/AN/A$0.12 per share1.67
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
$10K1,128.43N/AN/A$0.02 per share1.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
-$14.73M-$0.25N/AN/AN/AN/A-56.48%-29.07%N/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
-$25.70M-$0.12N/AN/AN/A20.88%-1,996.22%14.25%N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$10.35M-$3.89N/AN/AN/AN/A-166.11%-102.20%N/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
-$9.01MN/AN/AN/AN/AN/A-117.92%-102.44%N/A

Latest MTNB, ATBPF, NEVPF, and MRVFF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$0.21N/A-$0.21N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/AN/AN/AN/AN/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/A
10.06
10.06
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
9.97
2.11
1.77
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
0.85
0.85
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
7.99
7.99

Institutional Ownership

CompanyInstitutional Ownership
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
N/A
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
N/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A

Insider Ownership

CompanyInsider Ownership
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
9.00%
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
7.00%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Antibe Therapeutics Inc. stock logo
ATBPF
Antibe Therapeutics
1152.98 million48.24 millionNot Optionable
Nuvo Pharmaceuticals Inc. stock logo
MRVFF
Nuvo Pharmaceuticals
10011.40 million10.60 millionNot Optionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
3014.69 million14.02 millionN/A
Abliva AB (publ) stock logo
NEVPF
Abliva AB (publ)
8403.01 millionN/ANot Optionable

Recent News About These Companies

Pharming announces public cash offer to shareholders of Abliva AB
December 16, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/pharming-announces-public-cash-offer-to-shareholders-of-abliva-ab-1034139203
Stillfront Group publ AB (SFRG)
July 27, 2024  |  investing.comhttps://www.investing.com/equities/stillfront-group-publ-ab
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
July 19, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/abliva-announces-positive-interim-analysis-of-the-falcon-study-for-kl1333-in-primary-mitochondrial-disease-1033570295
Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024
May 13, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/abliva-host-virtual-kol-event-123000799.html?.tsrc=rss
Probi AB
March 20, 2024  |  barrons.comhttps://www.barrons.com/market-data/stocks/prob/company-people?countrycode=se
IVSXF Investor AB (publ)
January 9, 2024  |  seekingalpha.comhttps://seekingalpha.com/symbol/IVSXF
Interfox Resources publ AB (IFOX)
October 2, 2023  |  investing.comhttps://www.investing.com/equities/interfox-resources-publ-ab-historical-data
Oklahoma public higher ed leaders work to climb back from decade of cuts
March 19, 2023  |  tulsaworld.comT
Orangeburg Department of Public Safety: Woman reports sexual assault
March 18, 2023  |  thetandd.comT
Resolutions at the Extraordinary General Meeting in Abliva AB (publ)
March 10, 2023  |  privataaffarer.seP
Cell Impact publ AB (CELLI)
October 14, 2022  |  investing.comhttps://www.investing.com/equities/cell-impact-publ-ab
Abliva AB (publ) (NEVPF)
January 20, 2022  |  nasdaq.comhttps://www.nasdaq.com/market-activity/stocks/nevpf/press-releases?random=61e763eadc70b

Media Sentiment Over Time

Antibe Therapeutics stock logo

Antibe Therapeutics OTCMKTS:ATBPF

$0.22 0.00 (0.00%)
As of 08/28/2026

Antibe Therapeutics Inc., a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead compound is Otenaproxesul, an NSAID that releases hydrogen sulfide for treating post-operative pain, migraine, acute musculoskeletal pain, dysmenorrhea, gout, and dental pain. In addition, its products comprise ATB-352, which is in preclinical stage for acute pain. The company was incorporated in 2009 and is headquartered in Toronto, Canada.

Nuvo Pharmaceuticals stock logo

Nuvo Pharmaceuticals OTCMKTS:MRVFF

$0.98 0.00 (0.00%)
As of 03/16/2023

Nuvo Pharmaceuticals, Inc. is a pharmaceutical company, which is engaged in developing innovative therapeutic pharmaceutical products. It operates through the following segments: Commercial Business, Production and Service Business, and Licensing and Royalty Business. The Commercial Business segment includes Blexten, Cambia, the canadian business for Resultz and Suvexx, and mature assets. The Production and Service Business segment supplies Pennsaid to Horizon for the U.S. market and is engaged in ongoing partnering efforts for Pennsaid. The Licensing and Royalty Business segment engages in the selling of Vimovo. The company was founded on August 22, 1983 and is headquartered in Mississauga, Canada.

Matinas Biopharma stock logo

Matinas Biopharma NYSEAMERICAN:MTNB

$0.20 0.00 (0.00%)
As of 08/28/2026 04:10 PM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Abliva AB (publ) stock logo

Abliva AB (publ) OTCMKTS:NEVPF

$0.03 0.00 (0.00%)
As of 08/28/2026

Abliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas